Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum VEGF as a diagnostic marker during Lucentis treatment for macular edema due to retinal vein occlusion
2013-004656-38Phase 4Completed
- Sponsor
- Prof. Dr. Karl-Heinz Emmerich
- Start
- Nov 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in Vein occlusion (RVO) and central retinal vein occlusion (CRVO), sponsored by Prof. Dr. Karl-Heinz Emmerich. Primary endpoint: Serum VEGF level. Started Nov 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
Vein occlusion (RVO)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2013-004656-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004656-38.